This stock was sold off in a very similar pattern with many other biotech stocks.
We really need a stock pickers market to move way up where it belongs. I'm hoping that the investor conference next week will help. I think we would drift higher even without it, but it should help introduce the value play here. This company finances all of it's R&D from the P&L and does not eat up any of it's cash. That's virtually unheard of in the biotech market.